QUESTIONS FOR YOUR DOCTOR
What You Can Learn From the Studies
Each answer says which people joined and how their health changed. It can’t choose care, promise a result, or give dose advice.
What does semaglutide act like in your body?
Semaglutide joins 31-amino-acid parts. It acts like GLP-1, a gut hormone that helps with fullness and insulin. Two small changes slow the body’s breakdown of this GLP-1 medicine. A fat-like part helps it last about one week. The FDA approved this GLP-1 medicine for type 2 diabetes, weight control, and some heart risks. In 2023, a study followed 17,604 adults. The main heart risk fell by 20% [3]. You can ask what that finding could mean for your heart. You’ll have one clear heart question to bring.
Which health needs have semaglutide approval?
FDA-approved uses include type 2 diabetes, lasting weight control, and lower heart risk for some adults with excess weight. In 2025, approval grew to a liver disease in which fat causes swelling and scars. One study, named STEP 1, ran for 68 weeks and found more weight loss with semaglutide than placebo [4]. Another found a 24% drop in the main kidney risk among people with type 2 diabetes and long-term kidney disease [2]. Ask whether one approved use fits your health.
How can semaglutide affect hunger and blood sugar?
Semaglutide acts like GLP-1, a gut hormone. When blood sugar rises, it helps your pancreas release insulin. Food also leaves your stomach more slowly. In rats, semaglutide reached brain areas involved in hunger. The rats ate less while burning about the same number of calories [6]. Those actions may help explain changes in human blood sugar and weight. They don’t mean everyone feels less hunger. Ask which changes you may notice and what your doctor would check.
Why can weight drop with semaglutide?
The GLP-1 gut hormone followed by semaglutide may calm parts of the brain that drive eating. Rat work didn’t show a rise in calories burned [6]. Slower movement of food from your stomach may help you feel full sooner. In STEP 1, people taking semaglutide lost more weight. In a direct test named SURMOUNT-5, tirzepatide brought more weight loss by 72 weeks [1]. I’d ask which amount of change could help your health beyond the scale. Your result may differ.
How does tirzepatide differ from semaglutide?
Tirzepatide joins 39-amino-acid parts. It follows GLP-1 and a second gut hormone, while semaglutide follows only GLP-1. The FDA approved tirzepatide for type 2 diabetes, weight control, and sleep apnea in adults with obesity. Its second hormone action may add help with insulin and hunger. Studies named SURMOUNT-5 and SURPASS-2 found larger drops in weight and blood sugar than with semaglutide [1][11]. You can ask whether people in those studies shared your main health problems.
How can tirzepatide change insulin and hunger?
Tirzepatide follows GLP-1 and a second hormone released by your gut after food. GLP-1 and the second hormone help the pancreas release insulin when sugar rises in your blood. They may also slow the stomach and ease hunger. A study named SURPASS-2 ran 40 weeks and compared the medicines. The semaglutide group received 1 mg, and every tirzepatide group lost more weight [11]. A medical review describes both hormone actions [8]. You can ask how often your blood sugar would be checked. That’s a practical question for your next visit.
What changed with tirzepatide, and what went wrong?
Tirzepatide can raise insulin when blood sugar is high. It can slow your stomach and curb hunger too. SURMOUNT-1 followed adults without diabetes for 72 weeks. The 15 mg group lost far more weight than the placebo group [10]. Nausea, vomiting, and constipation were common, mainly as study amounts rose. A review found more gallbladder or bile-duct trouble when both problems were counted together [9]. Ask which side effects call for help.
Which health needs have tirzepatide approval?
The FDA first approved tirzepatide for type 2 diabetes in 2022. Later approvals cover lasting weight control and sleep apnea in adults with obesity. SURMOUNT-5 directly compared tirzepatide with semaglutide. Those taking tirzepatide lost more weight [1]. Approval means the FDA reviewed one use and found that known benefits outweighed known risks. It can’t promise the drug fits you. Ask what each approved use means for your care.
What is tesamorelin approved to change?
Tesamorelin acts like a hormone that speaks to your growth gland. The medicine joins 44-amino-acid parts, with one added part that slows breakdown in blood. In 2010, the FDA approved it to lower fat around the organs in adults with HIV lipodystrophy. That means an uncommon shift in where fat gathers after HIV care. A 2026 review of five studies found less fat around the organs, across the trunk, and in the liver, plus more muscle and other tissue that wasn’t fat [12]. No other use has approval. Ask whether your health problem matches.
How does tesamorelin change deep belly fat?
Tesamorelin prompts the growth gland under your brain. The gland releases growth hormone, and the liver then makes IGF-1, a growth protein that works with that hormone. Together, growth hormone and IGF-1 help break down fat around the organs. This differs from taking growth hormone itself. A study found 18% less fat around the organs after 52 weeks in adults with HIV. The fat returned after people stopped [16]. A federal liver review gave tesamorelin an E rating, meaning clear liver injury is thought unlikely [13]. Ask how those findings apply to you.
How does tesamorelin affect the growth gland?
Tesamorelin reaches the growth gland and starts the release of growth hormone. In a two-week test of 13 healthy men, growth hormone rose at night. A related growth protein, called IGF-1, rose by 181 micrograms per liter in a blood test. The men’s blood sugar control and fasting sugar didn’t clearly change [15]. The result shows that the gland answered the drug. It doesn’t prove broad health gains or show whether that rise stays safe for years. Ask how your hormone and blood sugar levels would be watched. You can ask what a change would mean for you.
Can tesamorelin reduce your belly fat?
Adults with HIV lipodystrophy lost some fat from around their organs while taking tesamorelin. That’s the group and health problem covered by FDA approval. Large studies haven’t proved the same result in people without that problem tied to HIV. Care for any other health need remains unproved. Even in the approved group, the organ fat began coming back soon after care ended [16]. Ask how closely you resemble the adults in that test. Also ask what may happen when care ends.
Does retatrutide have FDA approval?
No. Retatrutide still lacked FDA or other approval in mid-2026. It remains in Phase 3, the last big testing round before a company may ask for approval. Strong weight findings came from Phase 2, an earlier human round. One Phase 2 paper covered blood sugar. One group received 12 mg [20], and another test involved people with type 2 diabetes [21]. They're study results, rather than approved care. Products sold outside studies can’t be checked for contents or cleanliness. You can’t treat them as a known choice.
How may retatrutide change hunger and pulse?
Retatrutide follows GLP-1 and two other hormones: two from the gut and glucagon. The gut hormones may ease hunger and help insulin work after food. Glucagon may help the body use stored fuel. In cells kept in a dish, retatrutide reacted at the three places used by those hormones [18]. That work confirmed three actions, but it couldn’t show benefit or harm in a person. Glucagon can also speed the heart. In Phase 2, the pulse rise peaked near 24 weeks [20]. Bring your pulse and heart history to the visit. You won’t learn your own risk from a dish of cells.
What happened to people taking retatrutide?
In Phase 2, the 12 mg group lost much more weight over 48 weeks than the placebo group [20]. Blood sugar fell in people with type 2 diabetes who received 12 mg [21]. A separate 12 mg group had far less liver fat by 24 weeks, and 86% reached a normal level [19]. Nausea, constipation, and diarrhea were common. GLP-1, one gut hormone, may explain some stomach trouble. Glucagon may explain the faster pulse. Ask which finding best fits your health.
What did BPC-157 change in animals?
Most tests of this compound used rats. The compound helped new tiny blood vessels form and helped blood return to injured tissue [25]. Rat work also found signs of stomach-ulcer healing, tendon repair, and protection of the gut. Animal results can’t prove that BPC-157 heals you. A 2025 review found only three small human tests and zero large, strong studies [23]. Benefit and harm in people remain unclear. Your injury needs human proof before you trust a healing claim.
Is BPC-157 a form of growth hormone?
No. BPC-157 is man-made and based on part of a protein in stomach juice. It isn’t growth hormone and can’t replace that hormone. In animal work, tendon cells reacted more strongly to growth hormone after BPC-157. That result may help explain repair in rats. It doesn’t make the compound a growth hormone. It also can’t prove healing in a human tendon. Ask whether people with your tendon problem were studied.
How quickly does BPC-157 leave the blood?
Tests in rats and beagle dogs found that the compound left the blood fast. The whole compound stayed for less than 30 minutes, then split into protein parts [24]. The body could clear those parts or reuse them to make protein. Repair in animals took days or weeks to measure, so it wasn’t instant. Human studies haven’t found a sound time frame. A short stay in blood can’t tell you when your injury might change.
Does BPC-157 appear to harm the liver?
The few human results don’t show liver harm, but they’re much too small to settle safety. In 2025, two healthy adults received BPC-157 through a vein. Their liver blood tests didn’t clearly change, and neither had a quick bad effect [22]. Two people can’t settle safety. Another 2025 review found only three small human tests and no large study [23]. The liver risk from BPC-157 in people remains unknown. Ask how that unknown bears on your health.